We recommend hemodynamically stable patients do not routinely receive inotropes like dobutamine, dopamine or milrinone (Recommendation Strong, Quality High).

Values and Preferences These recommendations for inotropes place high value on the potential harm demonstrated when systematically studied in clinical trials and less value on potential short term hemodynamic effects of inotropes.